The UAE commenced the first Phase III clinical trials of Sinopharm CNBG’s Inactivated Vaccine for COVID-19. Department of Health (DOH) - Abu Dhabi Chairman H.E. Sheikh Abdullah bin Mohammed Al Hamed is the first volunteer to receive the clinical trial, with the Department's Acting Undersecretary, Dr Jamal Al Kaabi, to serve as the second volunteer. G42 Healthcare will conduct the vaccination trials in coordination with the Abu Dhabi Health Services (SEHA) as administered by the UAE Ministry of Health (MOH) and DOH-Abu Dhabi. SEHA operates the trials being conducted at five facilities, including a mobile clinic, in Abu Dhabi and Al Ain.
The Phase I and Phase II trials conducted by Sinopharm in China resulted in 100% of the volunteers generating antibodies after two doses in 28 days, paving the way to the conduct of the Phase III clinical trials. The Phase III trials, which will last for three to six months, allows the participation of volunteers aged between 18 and 60 living in Abu Dhabi and Al Ain. The Ethics Committee for Scientific Research in the Emirate of Abu Dhabi will approve and accredit the study if proven successful.
UAE at the Forefront of the Pandemic Battle
On July 16, the first group of volunteers which include UAE nationals and expats have received the vaccine at Sheikh Khalifa Medical City. The trials were conducted in the presence in the presence of the H.E Ni Jian, Chinese Ambassador to the UAE, senior health department officials, as well as representatives from G42 Healthcare and Sinopharm CNBG.
Being a melting pot of over 200 nationalities, the UAE can accommodate robust research of the vaccine trials across multiple ethnicities, making the country a preferred choice to conduct the Phase III trials. The country has issued permits to 15,000 volunteers to participate in the trials. In the first stage of the trials, G42 Healthcare and SEHA aims to conduct trials to a minimum of 5,000 participants.
The participation in the trials enables the country to “make a major contribution in the global fight to combat the COVID-19 pandemic,” according to Dr Nawal Ahmed Alkaabi, AE Principle Investigator Sheikh Khalifa Medical City CMO and Chairperson of the National COVID-19 Clinical Management Committee.
G42 Healthcare’s Role in the UAE’s COVID-19 Fight
G42 Healthcare has taken quick and crucial steps in establishing a massive testing laboratory, manufacturing personal protective equipment, conducting medical research, and using advanced AI technology to study the current pandemic trend in the country.
The institution is using its competitive advantage of having cutting-edge computing power and analytics in enabling research to deliver the world’s first Phase III vaccine trials. G42 Healthcare CEO Ashish Koshy stated that the company is “enormously proud” that Sinopharm CNBG has partnered with the company in the groundbreaking trials in the country. “Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, G42 Healthcare is uniquely postured to conduct these trials.”